No headlines found.
No press releases found.
No news found.
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.
Cytomed Therapeutics Limited - trades on the NASDAQ stock market under the symbol GDTC.
As of September 21, 2026, GDTC stock price declined to $0.97 with 32,289 million shares trading.
GDTC has a beta of -0.16, meaning it tends to be less sensitive to market movements. GDTC has a correlation of 0.00 to the broad based SPY ETF.
GDTC has a market cap of $11.48 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, GDTC traded as high as $5.50 and as low as $.68.
GDTC has underperformed the market in the last year with a return of -48.4%, while the SPY ETF gained +18.5%. In the last 3 month period, GDTC fell short of the market, returning -12.6%, while SPY returned +3.8%. However, in the most recent 2 weeks GDTC has outperformed the stock market by returning +12.6%, while SPY returned +0.7%.
GDTC support price is $.88 and resistance is $1.08 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that GDTC shares will trade within this expected range on the day.
